Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

"October's healthy sales boost is a welcome development for buyers and sellers alike,” said Baldev Gill, CEO of the Fraser ...

"Our preclinical data highlight the potential of azelaprag as a novel oral therapy for obesity," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. “Our two presentations provide evidence ...

Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount ...

BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy September 26, 2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug ...

Robust debuts by drug developers Bicara Therapeutics , MBX Biosciences, BioAge Labs and Upstream Bio are also encouraging potential candidates in the sector to move ahead with their listings. Septerna ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today ...

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead ...